22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › Arcutis Biotherapeutics, Inc. › 2024-2025

Arcutis Biotherapeutics, Inc. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Arcutis Biotherapeutics, Inc.’s Form 8-K, filed June 17, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 217Asset managers, any item
  • 1,143Fund votes
  • June 12, 2025Meeting date

Results at a glance

Meeting of June 12, 2025: 5 items on Arcutis Biotherapeutics, Inc.’s Form 8-K, filed June 17, 2025: 5 passed (calculated).

Dissent

Significant dissent: 2 directors (25.6%, 21.5% against).

Notable dissent: 1 director (15.0% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Rubric Capital (13F, 6.7%, as of September 30, 2026)

Explore Arcutis Biotherapeutics, Inc. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by Arcutis Biotherapeutics, Inc.

These tallies are Arcutis Biotherapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 17, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Arcutis Biotherapeutics, Inc. — official shareholder meeting results, meeting held June 12, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Bhaskar Chaudhuri, Ph.D. 69,994,307---- 19,137,53214,767,325 79%Passed (calculated)—
Elect Director: Sue-Jean Lin 75,774,723---- 13,357,11614,767,325 85%Passed (calculated)—
Elect Director: Howard G. Welgus, M.D. 66,289,952---- 22,841,88714,767,325 74%Passed (calculated)—
2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025 103,482,80747,951368,406 ---- 99.9%Passed (calculated)—
3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers 74,469,06013,477,5861,185,193 --14,767,325 85%Passed (calculated)—

Source: Arcutis Biotherapeutics, Inc., Form 8-K, filed with the SEC on June 17, 2025 — read the filing on EDGAR.

How asset managers voted at the Arcutis Biotherapeutics, Inc. 2024-2025 meeting

217 asset managers disclosed a vote on at least one Arcutis Biotherapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Bhaskar Chaudhuri, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%WITHHELD
FOR: 69,994,307WITHHELD: 19,137,532
Details: description as filed, official tally, votes by 62 asset managers

Description as filed by funds: Election of Class II Directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Bhaskar Chaudhuri, Ph.D.

Arcutis Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Bhaskar Chaudhuri, Ph.D.”): 69,994,307 for, 19,137,532 withheld, per its Form 8-K filed June 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 62 asset managers below reported 18,555,129 for, 9,168,246 withheld.

FORWITHHOLD
FOR: 18,555,129WITHHOLD: 9,168,246
Largest asset managers voting on “Election of Class II Directors to hold office until the 2028 Annual Meeting of Stockholders or until their suc” at Arcutis Biotherapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard6,679,1580 06,400For
Prudential/PGIM5,192,6240 00For
BlackRock00 02,913,115Withhold
Fidelity2,280,5580 0144,841Mixed
American Century00 01,342,139Withhold
FRANKLIN STRATEGIC SERIES965,5450 00For
State Street877,1160 01,115For
Charles Schwab00 0873,071Withhold
Invesco00 0826,702Withhold
TIAA803,7170 00For
Federated Hermes683,7220 00For
Aberdeen00 0675,034Withhold
First Trust00 0343,248Withhold
Royce339,3990 00For
AMG FUNDS284,8060 00For
Equitable00 0283,740Withhold
AIG/SunAmerica00 0245,184Withhold
John Hancock182,4660 038,164Mixed
SEI00 0200,058Withhold
Lincoln Financial78,9000 0108,569Mixed
DRIEHAUS MUTUAL FUNDS00 0179,695Withhold
QUANTITATIVE MASTER SERIES LLC00 0143,879Withhold
WESMARK FUNDS00 0102,700Withhold
Lazard00 083,302Withhold
RBB FUND, INC.00 079,198Withhold

Showing the 25 largest of 62 asset managers. All 62 are in the interactive database (link above).

Elect Director: Howard G. Welgus, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD
FOR: 66,289,952WITHHELD: 22,841,887
Details: description as filed, official tally, votes by 62 asset managers

Description as filed by funds: Election of Class II Directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Howard G. Welgus, M.D.

Arcutis Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Howard G. Welgus, M.D.”): 66,289,952 for, 22,841,887 withheld, per its Form 8-K filed June 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 62 asset managers below reported 16,849,027 for, 10,874,348 withheld.

FORWITHHOLD
FOR: 16,849,027WITHHOLD: 10,874,348
Largest asset managers voting on “Election of Class II Directors to hold office until the 2028 Annual Meeting of Stockholders or until their suc” at Arcutis Biotherapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard6,679,1580 06,400For
Prudential/PGIM5,192,6240 00For
BlackRock00 02,913,115Withhold
Fidelity2,280,5580 0144,841Mixed
American Century00 01,342,139Withhold
FRANKLIN STRATEGIC SERIES965,5450 00For
State Street2,4820 0875,749Withhold
Charles Schwab00 0873,071Withhold
Invesco00 0826,702Withhold
TIAA00 0803,717Withhold
Federated Hermes683,7220 00For
Aberdeen00 0675,034Withhold
First Trust00 0343,248Withhold
Royce339,3990 00For
AMG FUNDS284,8060 00For
Equitable00 0283,740Withhold
AIG/SunAmerica00 0245,184Withhold
John Hancock182,4660 038,164Mixed
SEI00 0200,058Withhold
Lincoln Financial39,6290 0147,840Mixed
DRIEHAUS MUTUAL FUNDS00 0179,695Withhold
QUANTITATIVE MASTER SERIES LLC00 0143,879Withhold
WESMARK FUNDS00 0102,700Withhold
Lazard00 083,302Withhold
RBB FUND, INC.00 079,198Withhold

Showing the 25 largest of 62 asset managers. All 62 are in the interactive database (link above).

Elect Director: Sue-Jean Lin

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD
FOR: 75,774,723WITHHELD: 13,357,116
Details: description as filed, official tally, votes by 62 asset managers

Description as filed by funds: Election of Class II Directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Sue-Jean Lin

Arcutis Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Sue-Jean Lin”): 75,774,723 for, 13,357,116 withheld, per its Form 8-K filed June 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 62 asset managers below reported 23,112,216 for, 4,611,159 withheld.

FORWITHHOLD
FOR: 23,112,216WITHHOLD: 4,611,159
Largest asset managers voting on “Election of Class II Directors to hold office until the 2028 Annual Meeting of Stockholders or until their suc” at Arcutis Biotherapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard6,679,1580 06,400For
Prudential/PGIM5,192,6240 00For
BlackRock2,913,1150 00For
Fidelity2,417,1990 08,200For
American Century00 01,342,139Withhold
FRANKLIN STRATEGIC SERIES965,5450 00For
State Street2,4820 0875,749Withhold
Charles Schwab873,0710 00For
Invesco826,7020 00For
TIAA803,7170 00For
Federated Hermes683,7220 00For
Aberdeen00 0675,034Withhold
First Trust00 0343,248Withhold
Royce339,3990 00For
AMG FUNDS284,8060 00For
Equitable170,3800 0113,360Mixed
AIG/SunAmerica00 0245,184Withhold
John Hancock182,4660 038,164Mixed
SEI200,0580 00For
Lincoln Financial39,6290 0147,840Mixed
DRIEHAUS MUTUAL FUNDS00 0179,695Withhold
QUANTITATIVE MASTER SERIES LLC143,8790 00For
WESMARK FUNDS00 0102,700Withhold
Lazard00 083,302Withhold
RBB FUND, INC.00 079,198Withhold

Showing the 25 largest of 62 asset managers. All 62 are in the interactive database (link above).

Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 8 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%AGAINST
FOR: 74,469,060AGAINST: 13,477,586

Prior year: 68.0% for (June 14, 2024 meeting) ▲ 16.6 pts

Details: description as filed, official tally, votes by 217 asset managers

Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.

Arcutis Biotherapeutics, Inc.’s own tally for this item (“3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers”): 74,469,060 for, 13,477,586 against, per its Form 8-K filed June 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 85% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 62 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.” at Arcutis Biotherapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard6,679,1586,400 00For
Prudential/PGIM5,192,6240 00For
BlackRock2,913,1150 00For
Fidelity136,6412,288,758 00Mixed
American Century01,342,139 00Against
FRANKLIN STRATEGIC SERIES965,5450 00For
State Street877,1161,115 00For
Charles Schwab873,0710 00For
Invesco0826,702 00Against
TIAA803,7170 00For
Federated Hermes683,7220 00For
Aberdeen0675,034 00Against
Simplify Exchange Traded Funds657,1340 00For
First Trust0343,248 00Against
Royce00 339,3990Abstain
AMG FUNDS284,8060 00For
Equitable170,380113,360 00Mixed
AIG/SunAmerica0245,184 00Against
John Hancock182,46638,164 00Mixed
SEI200,0580 00For
Lincoln Financial118,52968,940 00Mixed
DRIEHAUS MUTUAL FUNDS0179,695 00Against
QUANTITATIVE MASTER SERIES LLC143,8790 00For
WESMARK FUNDS0102,700 00Against
Lazard083,302 00Against

Fund voting reports, all 62 managers: 21,303,344 for, 6,727,479 against, 345,840 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 177 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.” at Arcutis Biotherapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
SUVRETTA CAPITAL MANAGEMENT, LLC10,584,8660 00For
Frazier Life Sciences Management, L.P.9,769,5110 00For
JENNISON ASSOCIATES LLC8,744,0060 00For
Rubric Capital Management LP7,272,4830 00For
State Street3,078,24851,121 00For
FRANKLIN ADVISERS INC2,651,44268,940 00For
BlackRock2,633,39927,185 00For
GEODE CAPITAL MANAGEMENT, LLC02,565,962 00Against
Ensign Peak Advisors, Inc2,001,4390 00For
Paradigm Biocapital Advisors LP01,519,214 00Against
American Century01,416,587 00Against
GW&K Investment Management, LLC1,190,0090 00For
J. Goldman & Co LP1,055,8570 00For
Invesco0878,505 00Against
Charles Schwab873,3850 00For
Nuveen815,8160 00For
PFM Health Sciences, LP0705,685 00Against
Federated Hermes701,5120 00For
UniSuper Management Pty Ltd700,0000 00For
Aberdeen0675,034 00Against
DRIEHAUS CAPITAL MANAGEMENT LLC0667,447 00Against
Prudential/PGIM591,6150 00For
Northern Trust460,53410,235 00For
Cormorant Asset Management, LP440,8170 00For
Cercano Management LLC0426,101 00Against

Institutional-manager reports, all 177 managers: 56,050,342 for, 11,035,805 against, 259 not voted. Showing the 25 largest; every one is in the interactive database (link above).

The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 103,482,807AGAINST: 47,951

Prior year: 100.0% for (June 14, 2024 meeting) unchanged

Details: description as filed, official tally, votes by 62 asset managers

Description as filed by funds: To ratify the selection, by the Audit Committee of the Company's Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.

Arcutis Biotherapeutics, Inc.’s own tally for this item (“2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 20”): 103,482,807 for, 47,951 against, per its Form 8-K filed June 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 62 asset managers below reported 27,716,934 for, 6,441 abstained.

FOR
FOR: 27,716,934ABSTAIN: 6,441
Largest asset managers voting on “To ratify the selection, by the Audit Committee of the Company's Board of Directors, of Ernst & Young LLP, as ” at Arcutis Biotherapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard6,685,5580 00For
Prudential/PGIM5,192,6240 00For
BlackRock2,913,1150 00For
Fidelity2,425,3990 00For
American Century1,342,1390 00For
FRANKLIN STRATEGIC SERIES965,5450 00For
State Street878,2310 00For
Charles Schwab873,0710 00For
Invesco826,7020 00For
TIAA803,7170 00For
Federated Hermes683,7220 00For
Aberdeen675,0340 00For
First Trust343,2480 00For
Royce339,3990 00For
AMG FUNDS284,8060 00For
Equitable283,7400 00For
AIG/SunAmerica245,1840 00For
John Hancock220,6300 00For
SEI200,0580 00For
Lincoln Financial187,4690 00For
DRIEHAUS MUTUAL FUNDS179,6950 00For
QUANTITATIVE MASTER SERIES LLC143,8790 00For
WESMARK FUNDS102,7000 00For
Lazard83,3020 00For
RBB FUND, INC.79,1980 00For

Showing the 25 largest of 62 asset managers. All 62 are in the interactive database (link above).

Largest Arcutis Biotherapeutics, Inc. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 119,137,785 shares outstanding at the time of that meeting.

Fund voting reports: top Arcutis Biotherapeutics, Inc. shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive…”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 5.61%
2Prudential/PGIM 4.36%
3BlackRock 2.45%
4Fidelity 2.04%
5American Century 1.13%
6FRANKLIN STRATEGIC SERIES 0.81%
7State Street 0.74%
8Charles Schwab 0.73%
9Invesco 0.69%
10TIAA 0.67%
Institutional-manager reports: top Arcutis Biotherapeutics, Inc. shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive…”, 2024-2025
#Asset manager % of shares outstanding
1SUVRETTA CAPITAL MANAGEMENT, LLC 8.88%
2Frazier Life Sciences Management, L.P. 8.20%
3JENNISON ASSOCIATES LLC 7.34%
4Rubric Capital Management LP 6.10%
5State Street 2.63%
6FRANKLIN ADVISERS INC 2.28%
7BlackRock 2.23%
8GEODE CAPITAL MANAGEMENT, LLC 2.15%
9Ensign Peak Advisors, Inc 1.68%
10Paradigm Biocapital Advisors LP 1.28%

Reported Arcutis Biotherapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Arcutis Biotherapeutics, Inc. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Suvretta Capital Management, LLC9,534,837 8.00%Proxy statement (DEF 14A), proxy filed April 29, 2025
BlackRock8,892,337 7.46%Form 13F, quarter ended March 31, 2025
Patrick J. Heron8,793,971 7.38%Proxy statement (DEF 14A), proxy filed April 29, 2025
Frazier Life Sciences VIII, L.P.8,785,284 7.37%Schedule 13D, filed August 20, 2025
Rubric Capital Management LP8,271,577 6.94%Schedule 13G, filed February 13, 2026
Vanguard Group6,818,078 5.72%Form 13F, quarter ended March 31, 2025
Polar Capital Holdings Plc6,297,688 5.29%Proxy statement (DEF 14A), proxy filed April 29, 2025
PRUDENTIAL FINANCIAL INC5,302,713 4.45%Schedule 13G, filed May 8, 2026
Jennison Associates LLC4,980,770 4.18%Schedule 13G, filed May 6, 2026
State Street4,474,203 3.76%Form 13F, quarter ended March 31, 2025

Percentages above are of 119,137,785 shares outstanding, as reported by Arcutis Biotherapeutics, Inc. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Arcutis Biotherapeutics, Inc.'s shareholder meeting held June 12, 2025, in the 2024-2025 proxy season, 217 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,143 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of the Company's named executive… — FOR was 85% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Arcutis Biotherapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 17, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Arcutis Biotherapeutics, Inc.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Arcutis Biotherapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “Arcutis Biotherapeutics (ARQT) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/arcutis-biotherapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.